Press Release
<< Back
Verastem Promotes Chief Operating Officer Robert Forrester to President
“Verastem has rapidly progressed through Robert’s dedication and
outstanding execution across all aspects of the Company,” said
In 2012,
“Robert has been instrumental as
“It is my honor and pleasure to work with Christoph and the entire
Mr. Forrester has been the CEO, COO and CFO of both private and public
biotechnology companies. Prior to his industry leadership experience,
Robert oversaw investments in the life sciences industry as a managing
director at MeesPierson. At BZW and UBS, Robert was responsible for
corporate transactions including M&A, public and private financings.
Robert started his career as lawyer with
About Verastem, Inc.
Forward-looking statements:
This press release includes forward-looking statements about the
Company’s strategy, future plans and prospects, including statements
regarding the development of the Company’s compounds, including VS-6063,
the timeline for clinical development and regulatory approval of the
Company’s compounds and the structure of the Company’s planned clinical
trials. The words “anticipate,” “believe,” “estimate,” “expect,”
“intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,”
“will,” “would,” “could,” “should,” “continue,” and similar expressions
are intended to identify forward-looking statements, although not all
forward-looking statements contain these identifying words. Each
forward-looking statement is subject to risks and uncertainties that
could cause actual results to differ materially from those expressed or
implied in such statement. Applicable risks and uncertainties include
the risks that the preclinical testing of the Company’s compounds may
not be predictive of the success of later clinical trials, that the
Company will be unable to successfully complete the clinical development
of its compounds, that the development of the Company’s compounds will
take longer or cost more than planned, and that the Company’s compounds
will not receive regulatory approval or become commercially successful
products. Other risks and uncertainties include those identified under
the heading “Risk Factors” in the Company’s Annual Report on Form 10-K
for the year ended
Source:
Verastem, Inc.
Investor contact:
Brian Sullivan,
617-252-9314
bsullivan@verastem.com
or
Media
contact:
Kari Watson, 781-235-3060
kwatson@macbiocom.com